Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism
Mehrdad Hashem,Elaheh Mohandesi Khosroshahi,Melika Aliahmady,Morvarid Ghanei,Yasamin Soofi Rezaei,Yasamin alsadat Jafari,Fateme rezaei,Ramtin Khodaparast eskadehi,Kimia Kia Kojoori,faranak jamshidian,Noushin Nabavi,Mohsen Rashidi,Farzaneh Hasani Sadi,Afshin taheriazam,Maliheh Entezari
DOI: https://doi.org/10.1016/j.ncrna.2024.01.009
2024-01-24
Non-coding RNA Research
Abstract:Highlights • Bladder cancer (BC) is a prevalent urogenital malignancy that is conventionally cured by cisplatin chemo drug. • The chemo-resistant phenotype undesirably results in BC cells resistance in response to cisplatin. • Non-coding RNAs (ncRNAs) have been potentially identified to serve as cisplatin resistance mediators during BC. • The corresponding regulatory network is principally conducted through diverse cellular processes and signaling pathways. • These ncRNAs have also opened insights into BC diagnosis and prognosis. Bladder cancer (BC) is a highly frequent neoplasm in correlation with significant rate of morbidity, mortality, and cost. The onset of BC is predominantly triggered by environmental and/or occupational exposures to carcinogens, such as tobacco. There are two distinct pathways by which BC can be developed, including non-muscle-invasive papillary tumors (NMIBC) and non-papillary (or solid) muscle-invasive tumors (MIBC). The Cancer Genome Atlas project has further recognized key genetic drivers of MIBC along with its subtypes with particular properties and therapeutic responses; nonetheless, NMIBC is the predominant BC presentation among the suffering individuals. Radical cystoprostatectomy, radiotherapy, and chemotherapy have been verified to be the common therapeutic interventions in metastatic tumors, among which chemotherapeutics are more conventionally utilized. Although multiple chemo drugs have been broadly administered for BC treatment, cisplatin is reportedly the most effective chemo drug against the corresponding malignancy. Notwithstanding, tumor recurrence is usually occurred following the consumption of cisplatin regimens, particularly due to the progression of chemo-resistant trait. In this framework, non-coding RNAs (ncRNAs), as abundant RNA transcripts arise from the human genome, are introduced to serve as crucial contributors to tumor expansion and cisplatin chemo-resistance in bladder neoplasm. In the current review, we first investigated the best-known ncRNAs, i.e. microRNAs (miRNAs), long ncRNAs (lncRNAs), and circular RNAs (circRNAs), correlated with cisplatin chemo-resistance in BC cells and tissues. We noticed that these ncRNAs could mediate the BC-related cisplatin-resistant phenotype through diverse cellular processes and signaling mechanisms, reviewed here. Eventually, diagnostic and prognostic potential of ncRNAs, as well as their therapeutic capabilities were highlighted in regard to BC management. Graphical abstract Download : Download high-res image (155KB) Download : Download full-size image
biochemistry & molecular biology